Tuesday, July 24, 2012

Afinitor Approved for HR+ve breast cancer - Biocon to benefit

Biocon is the only Indian company to have launched a generic version of Afinitor in India and is sold under  the brand name Evertor.  A couple of days back, Afinitor received approval from the USFDA for the  treatment of HR+ve breast cancer.  The approval is based on breakthrough survival benefit (Median PFS was 11 months versus 4.1months with exemestane alone) demonstrated by Afinitor in patients with HR+ve and HER2-ve breast cancer  who have previously failed  Letrozole/Anastrazole therapy.    The global market  potential for this indication for Afinitor is $1.5billion. Assuming a 95% discount to Afinitor price for Evertor in India, the drug may potentially fetch an incremental 100 cr for  Biocon in incremental revenues
.

5 comments:

  1. Biocon may fetch more 100cr in incremental revenues as it is not chemical generic + these immunosuppressants r not easy to made.

    ReplyDelete
  2. Could be more than 100 crore. Do you have a clue on the pricing of Evertor?

    ReplyDelete
    Replies
    1. I think biocon is charging 60,000-80,000 per 10 strip tablets for this.

      Delete
  3. It is surprising, that during the conference call, when probed by an analyst, the company was caught unaware of this potential opportunity. It seems Biocon needs to focus for value in their existing portfolio, rather than wasting energy on stretched objectives (biologics NCE)

    ReplyDelete
    Replies
    1. I agree, they were caught unaware, but were able to reconcile soon. They accepted that the potential opportunity for them is about 80 crores..

      The net margin of such a high value product could add 25% on its existing bottom line.

      Delete